Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045229 | 0.91 | TLR7 (0.41) | TLR7KMT2ASIRT5LMNAMAPT | |
| SCHEMBL29991527 | 0.90 | TLR7 (0.41) | TLR7KMT2ASIRT5LMNAMAPT | |
| SCHEMBL31045226 | 0.90 | TLR7 (0.41) | TLR7KMT2ASIRT5LMNAMAPT | |
| SCHEMBL31044796 | 0.90 | TLR7 (0.43) | TLR7KMT2ASIRT5LMNAMAPT | |
| SCHEMBL31045198 | 0.88 | RAB9A (0.41) | TLR7KMT2ASIRT5LMNAMEN1 | |
| SCHEMBL20667981 | 0.87 | TLR7 (0.46) | TLR7KMT2ASIRT5MEN1CCNE2 | |
| SCHEMBL31045380 | 0.87 | TLR7 (0.46) | TLR7KMT2ASIRT5MEN1CCNE2 | |
| SCHEMBL31044831 | 0.84 | TLR7 (0.48) | TLR7KMT2ASIRT5LMNAMAPT | |
| SCHEMBL31044792 | 0.83 | APP (0.41) | TLR7KMT2ASIRT5MAPTHTT | |
| SCHEMBL31045335 | 0.83 | TLR7 (0.43) | TLR7KMT2ASIRT5MEN1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | TLR7 1209/4885KMT2A 4333/4885SIRT5 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.